21.03.2011 - Amgen said on Friday that European regulators have declined to recommend approval of its drug Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)